neuropeptide Y2 receptor

03/01/2006 - "Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men."
07/01/2009 - "[Association between obesity and the polymorphism of neuropeptide Y2 receptor gene in children and adolescents]."
11/01/2007 - "No association of sequence variants in the neuropeptide Y2 receptor (NPY2R) gene with early onset obesity in Germans."
07/01/2009 - "To study the relationship between neuropeptide Y2 receptor (NPY2R) gene rs1047214 polymorphism and obesity or metabolic syndrome in Chinese children and adolescents, in order to provide theoretical evidence for obesity control. "
09/01/2008 - "Ventromedial hypothalamic NPY Y2 receptor in the maintenance of body weight in diet-induced obesity in mice."

01/01/2016 - "These data suggest that administration of a NPY2 receptor antagonist may be effective for attenuating the anorexia caused by 5-FU chemotherapy."
12/01/2012 - "Food intake experiments using the NPY2 receptor antagonist BIIE0246 and the CCK1A receptor antagonist devazepide, individually, suggested that PYY mediated DON-induced anorexia but CCK did not. "

07/01/2009 - "To study the relationship between neuropeptide Y2 receptor (NPY2R) gene rs1047214 polymorphism and obesity or metabolic syndrome in Chinese children and adolescents, in order to provide theoretical evidence for obesity control. "

02/01/2016 - "In the present study, a conceptually novel framework reflecting a plausible clinical trial for gene therapy of temporal lobe epilepsy was explored: We investigated (i) whether the post intrahippocampal kainate-induced status epilepticus (SE) model of chronic epilepsy in rats could be clinically relevant; and (ii) whether a translationally designed neuropeptide Y (NPY)/Y2 receptor-based gene therapy approach targeting only the seizure-generating focus unilaterally can decrease seizure frequency in this chronic model of epilepsy. "

03/26/2015 - "Blockade of the NPY Y2 receptor suppressed tumor growth in obese mice by affecting tumor angiogenesis. "
03/26/2015 - "Administration of an NPY Y2 receptor antagonist decreased tumor angiogenesis (evaluated as capillary density/mm2) and serum VEGF concentration in the obese group without altering serum VEGF-R1 and NO concentrations. "
03/26/2015 - "The present study examined the effects of the NPY Y2 receptor antagonist on tumor weight, angiogenesis and serum levels of vascular endothelial growth factor (VEGF), VEGF receptor-1 (VEGF-R1), and nitric oxide (NO). "